Leonard Chiu1, Ronald Chow1, Marko Popovic1, Rudolph M Navari2, Nathan M Shumway3, Nicholas Chiu1, Henry Lam1, Milica Milakovic1, Mark Pasetka1, Sherlyn Vuong1, Edward Chow4,5, Carlo DeAngelis1. 1. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. 2. Indiana University School of Medicine, South Bend, IN, USA. 3. San Antonio Military Medical Center (SAMMC), San Antonio, TX, USA. 4. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. Edward.Chow@sunnybrook.ca. 5. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada, M4N 3M5. Edward.Chow@sunnybrook.ca.
Abstract
PURPOSE: Olanzapine is a potent antipsychotic medication that inhibits a wide variety of receptors. It has been used in trials for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV). This study systematically investigates the efficacy of olanzapine in relation to other antiemetics in the prophylaxis and rescue of CINV. METHODS: A literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing olanzapine to other standard antiemetics for either prevention or rescue. The primary endpoints were the percentage of patients achieving no emesis or no nausea, in the acute, delayed, and overall phases. RESULTS: Ten RCTs in the preventative setting and three RCTs in the breakthrough setting were identified. Subgroup analysis demonstrated a similar degree of benefit from a 5- and 10-mg dose of olanzapine for the no emesis endpoint in the overall phase. In the prophylaxis setting, olanzapine was statistically superior in five of six endpoints and clinically superior in four of six endpoints. In the breakthrough setting, olanzapine was statistically and clinically superior in the only endpoint analyzed: no emesis. CONCLUSION: Olanzapine is more efficacious than other standard antiemetics for the rescue of CINV and its inclusion improves control in the prevention setting. Given the possible reduction in side effects, the use of a 5-mg dose of olanzapine should be considered. Future RCTs should compare the 5-mg versus the 10-mg dosages further and report on the efficacy and percentage of patients developing side effects. Further analyses should be done without the influence of corticosteroids.
PURPOSE: Olanzapine is a potent antipsychotic medication that inhibits a wide variety of receptors. It has been used in trials for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV). This study systematically investigates the efficacy of olanzapine in relation to other antiemetics in the prophylaxis and rescue of CINV. METHODS: A literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing olanzapine to other standard antiemetics for either prevention or rescue. The primary endpoints were the percentage of patients achieving no emesis or no nausea, in the acute, delayed, and overall phases. RESULTS: Ten RCTs in the preventative setting and three RCTs in the breakthrough setting were identified. Subgroup analysis demonstrated a similar degree of benefit from a 5- and 10-mg dose of olanzapine for the no emesis endpoint in the overall phase. In the prophylaxis setting, olanzapine was statistically superior in five of six endpoints and clinically superior in four of six endpoints. In the breakthrough setting, olanzapine was statistically and clinically superior in the only endpoint analyzed: no emesis. CONCLUSION: Olanzapine is more efficacious than other standard antiemetics for the rescue of CINV and its inclusion improves control in the prevention setting. Given the possible reduction in side effects, the use of a 5-mg dose of olanzapine should be considered. Future RCTs should compare the 5-mg versus the 10-mg dosages further and report on the efficacy and percentage of patients developing side effects. Further analyses should be done without the influence of corticosteroids.
Entities:
Keywords:
Breakthrough emesis; Chemotherapy-induced nausea and vomiting; Efficacy; Olanzapine; Prophylaxis
Authors: F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr Journal: Ann Oncol Date: 2010-05 Impact factor: 32.976
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: Rudolph M Navari; Lawrence H Einhorn; Patrick J Loehrer; Steven D Passik; Jake Vinson; John McClean; Naveed Chowhan; Nasser H Hanna; Cynthia S Johnson Journal: Support Care Cancer Date: 2007-03-21 Impact factor: 3.603
Authors: Rudolph M Navari; Lawrence H Einhorn; Steven D Passik; Patrick J Loehrer; Cynthia Johnson; M L Mayer; J McClean; Jake Vinson; W Pletcher Journal: Support Care Cancer Date: 2005-02-08 Impact factor: 3.603
Authors: Ronald Chow; David G Warr; Rudolph M Navari; May Tsao; Marko Popovic; Leonard Chiu; Milica Milakovic; Henry Lam; Carlo DeAngelis Journal: Support Care Cancer Date: 2018-05-23 Impact factor: 3.603
Authors: Ronald Chow; Crystal Valdez; Natalie Chow; Daniel Zhang; James Im; Emily Sodhi; Michael Lock Journal: Support Care Cancer Date: 2020-01-08 Impact factor: 3.603
Authors: Sonam Puri; Kelly A Hyland; Kristine Crowe Weiss; Gillian C Bell; Jhanelle E Gray; Richard Kim; Hui-Yi Lin; Aasha I Hoogland; Brian D Gonzalez; Ashley M Nelson; Anita Y Kinney; Stacy M Fischer; Daneng Li; Paul B Jacobsen; Howard L McLeod; Heather S L Jim Journal: Support Care Cancer Date: 2018-03-15 Impact factor: 3.603
Authors: J Flank; T Schechter; P Gibson; D L Johnston; A D Orsey; C Portwine; L Sung; L L Dupuis Journal: Support Care Cancer Date: 2017-08-30 Impact factor: 3.603
Authors: Abdullah A Alhifany; Ali McBride; Abdulaali R Almutairi; Ejaz Cheema; Alaa Shahbar; Yasser Alatawi; Adnan S Alharbi; Hani Babiker; Karen MacDonald; Matti Aapro; Ivo Abraham Journal: Support Care Cancer Date: 2019-12-10 Impact factor: 3.603